What are the indications, dosing regimen, administration guidelines, and monitoring recommendations for intravenous immunoglobulin (IVIG) therapy?

IVIG Therapy: Indications, Dosing, Administration, and Monitoring

Primary Indications

IVIG is definitively indicated for primary immunodeficiency diseases (replacement therapy) and specific autoimmune/inflammatory conditions (immunomodulatory therapy), with dosing and monitoring protocols that must be strictly followed to minimize serious risks including thrombosis, renal failure, and hemolysis. 1

Replacement Therapy (Primary Immunodeficiency)

• Dose: 300-600 mg/kg every 3-4 weeks 2, 1
• Adjust based on clinical response and trough IgG levels
• For measles exposure: 400 mg/kg immediately (within 6 days) or maintain ≥530 mg/kg regular dosing for adequate protection 1

Immunomodulatory Therapy - FDA Approved and Guideline-Supported Uses

Immune Thrombocytopenia (ITP):

• First-line dose: 1 g/kg as single dose; may repeat if necessary 3
• Use with corticosteroids when rapid platelet increase required
• Use as monotherapy if corticosteroids contraindicated 3

Neuromuscular Disorders (Class I evidence):

• Chronic inflammatory demyelinating polyneuropathy (CIDP)
• Guillain-Barré Syndrome in adults
• Multifocal motor neuropathy
• Dermatomyositis (FDA-approved indication)
• Myasthenia gravis exacerbations (not stable disease)
• Stiff-person syndrome 4

Secondary ITP:

• HCV-associated ITP: IVIG is initial treatment of choice 3
• HIV-associated ITP: Use corticosteroids, IVIG, or anti-D if bleeding complications present 3

Pregnancy-related ITP: Corticosteroids or IVIG are recommended treatments 3

Administration Protocol

Infusion Rate (Critical for Safety)

Start conservatively and advance slowly 1:

• Initial rate: 0.01 mL/kg/min (0.5 mg/kg/min)
• Maintenance rate (if tolerated after 30 minutes): Gradually increase to maximum 0.10 mL/kg/min (5 mg/kg/min)
• Monitor vital signs continuously throughout infusion
• For high-risk patients (renal dysfunction, thrombosis risk): Use minimum dose and slowest tolerable rate 1

Preparation Requirements

• Inspect for particulates and turbidity - do not use if present 1
• Do not dilute with IV fluids 1
• Use separate IV line - do not mix with other medications 1
• Multiple vials may be pooled aseptically for large doses 1
• Use promptly once vial entered; discard unused portions 1
• Do not use if frozen 1

Route Considerations

• Avoid permanent central venous catheters solely for IVIG administration 2
• Consider subcutaneous immunoglobulin (SCIG) for difficult venous access 2

Monitoring Requirements

Pre-Treatment Screening (Essential)

Screen ALL patients for kidney disease and thrombosis risk factors before initiating IVIG 5:

• Baseline renal function (BUN, creatinine, urine output)
• Blood viscosity assessment in hyperviscosity-risk patients 1
• IgA levels (identify IgA deficiency with anti-IgA antibodies) 2, 1

Ongoing Monitoring

Regular monitoring every 6-12 months minimum 2:

• Trough IgG levels (pre-infusion for IV; steady-state for subcutaneous)
• Complete blood count
• Serum chemistry panel
• Renal function (especially in at-risk patients) 1, 5
• More frequent monitoring in growing children 2

During Infusion Vigilance

Monitor for:

• Thrombotic events (chest pain, dyspnea, leg swelling)
• Hemolysis (especially non-O blood groups, high doses) 1
• Transfusion-related acute lung injury (TRALI) 1
• Aseptic meningitis (high doses, rapid infusion) 1
• Anaphylaxis (particularly IgA-deficient patients) 2, 1

Critical Safety Warnings

Boxed Warning Conditions 1

Thrombosis Risk Factors:

• Advanced age
• Prolonged immobilization
• Hypercoagulable conditions
• History of venous/arterial thrombosis
• Estrogen use
• Indwelling vascular catheters
• Hyperviscosity
• Cardiovascular risk factors

Action: Ensure adequate hydration before administration; use minimum effective dose and rate 1

Renal Dysfunction Risk

• Higher risk with sucrose-containing products (Flebogamma 5% DIF contains sorbitol, not sucrose) 1
• Ensure patients not volume-depleted
• Discontinue if renal function deteriorates 1

Special Populations

IgA deficiency: Not a contraindication to therapy, but anaphylaxis risk exists with anti-IgA antibodies 2. Some patients tolerate subcutaneous route after IVIG anaphylaxis 2

Hereditary fructose intolerance: Contraindicated with sorbitol-containing products 1

Contraindications

Absolute contraindications 1:

• History of anaphylactic or severe systemic reactions to human immunoglobulin
• IgA-deficient patients with anti-IgA antibodies AND history of hypersensitivity

Adjunctive Therapy Considerations

For immunodeficient patients receiving IVIG 2:

• Aggressive antimicrobial therapy: Use higher doses and longer duration than standard
• Antimicrobial prophylaxis: Consider for recurrent infections (amoxicillin 10-20 mg/kg daily/BID for children; 500-1000 mg daily/BID for adults)
• PCP prophylaxis: For severe T-cell deficiency
• Vaccination: Passive antibody transfer may confound serologic testing 1